Bald eagle makes surprise appearance in Rankin Inlet
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
Article content SAN ANTONIO — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. Article content 'As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives,' said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. Article content 'We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science,' Ms. Zannes said. 'Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics.' Article content The Canadian patent (Patent No. 3,136,245) – titled 'System and Method for Determining Lung Health' – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. Article content CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Article content About CyPath® Lung Article content CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit Article content About bioAffinity Technologies, Inc. Article content bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Article content Forward-Looking Statements Article content Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Article content Article content Article content Article content Article content Contacts Article content bioAffinity Technologies Article content Article content Julie Anne Overton Article content Article content Director of Communications Article content Article content
CBC
6 hours ago
- CBC
A Chinese research vessel returns to Arctic waters — and it appears Canada is watching
Social Sharing The Canadian military and possibly the coast guard appear to have been keeping tabs on a Chinese research vessel as it returns to Arctic waters off Alaska for the second year in a row. Data compiled by an independent researcher and ship tracker, Steffan Watkins, shows a Canadian air force CP-140 surveillance plane was flying in the vicinity of the Xue Long (Snow Dragon) 2 as it exited the Bering Strait on Sunday. The aircraft, according to Watkins's research, relocated to Anchorage, Alaska, from its base in Comox, B.C., on July 9. It has conducted four patrols since then, including the most recent one involving the vessel, which is China's first domestically built polar research ship. Despite publicly available flight tracking showing the CP-140's patrol route, the Department of National Defence would not confirm on Monday the presence of the aircraft and said it couldn't immediately answer questions on the deployment. The air force appears to have picked up where the Canadian Coast Guard left off. Coast guard says it's monitoring illegal fishing The Chinese ice ship left Shanghai on July 6 and passed close to Japan a few days later, before heading north into Russian waters. "Shadowing the Xue Long 2 all of the way from Japan was CCGS Sir Wilfrid Laurier, which unmistakably paralleled their transit, staying in international waters," Watkins wrote in his latest post, which included ship-tracking data. The coast guard ship, the data shows, stuck with the Xue Long 2 until it crossed into the Bering Strait, between Alaska and Russia. Asked about the mission of the Sir Wilfrid Laurier, the coast guard at first provided a circumspect response and pointed CBC News to a June 9 media release which said the ship would be conducting high seas patrols in the North Pacific to counter "illegal, unreported and unregulated (IUU) fishing." Then late Monday, the agency denied it was shadowing the Xue Long 2. The stated mission of the coast guard ship was to focus on "migratory routes for key species like Pacific salmon," it said. However, when ship-tracking data is overlaid with publicly available data on salmon migration routes, only one-third of the recent voyage involved known salmon paths. The ship's helicopter was also slated to conduct patrols with Canadian fishery officers in Japan to "monitor fishing vessels and support partner countries to ensure compliance with international law," according to the statement. Prime Minister Mark Carney pledged to expand the reach, security mandate and abilities of the Canadian Coast Guard as part of the Liberal government's plan to beef up the country's defences. Eventually, the federal government intends to integrate the civilian agency, currently under the Fisheries Department, into Canada's NATO defence capabilities to, as Carney put it last June, "better secure our sovereignty and expand maritime surveillance." Last summer, the Royal Canadian Navy dispatched a frigate to monitor the Xue Long 2 during its voyage to the Arctic — a mission the Department of National Defence took more than a week to acknowledge. Military experts have described the Chinese ice research ship as a dual-use vessel — suggesting it has a military or defence capacity. WATCH | Canada plots military expansion in the North: Canada plans Arctic military expansion as part of sovereignty push 2 months ago University of British Columbia Arctic expert Michael Byers said he believes Canadian officials need to be more forthcoming about the security threat they believe the vessel poses. "One has to actually do a proper threat assessment," Byers told CBC News in an interview. Byers acknowledged the Chinese ship could be collecting data that's militarily relevant, but he questions if the term "dual-use" is relying on assumptions rather than evidence. Relations with China continue to be strained and Byers said statements that are "potentially escalatory" about what the Chinese are — and are not — doing in the Arctic need to be examined carefully. Having said that, he fully supports the military and coast guard's monitoring activities. "We're very concerned as a country about China as a rising military power, and obviously China is very strongly supporting Russia with regards to its invasion of Ukraine," Byers said.
CTV News
13 hours ago
- CTV News
Removing HIV stigma in Manitoba
Winnipeg Watch Researchers in Manitoba are looking to improve treatment and reduce the stigma for those living with HIV.
